Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis

Acta Trop. 2003 May;86(2-3):223-32. doi: 10.1016/s0001-706x(03)00042-1.

Abstract

Considerable experience and limited quantitative evidence indicate that infections with the soil-transmitted helminths Ascaris lumbricoides and Trichuris trichiura usually start to become established in children aged 12 months and older. Since children living in countries where the infections are endemic are at risk of morbidity, even those as young as 12 months may need to be considered for inclusion in public health programmes designed to reduce morbidity by means of regular anthelminthic chemotherapy. This situation raises the question as to whether such young children should be given anthelminthic drugs. Systems for the absorption, distribution, metabolism and elimination of drugs do not fully develop until children are in their second year of life. Current knowledge, however, reveals that the incidence of side effects linked to benzimidazole drugs in young children is likely to be the same as in older children. Accordingly, we conclude that albendazole and mebendazole may be used to treat children as young as 12 months if local circumstances show that relief from ascariasis and trichuriasis is justified.

Publication types

  • Review

MeSH terms

  • Animals
  • Anthelmintics / adverse effects
  • Anthelmintics / pharmacokinetics
  • Anthelmintics / therapeutic use
  • Benzimidazoles / adverse effects*
  • Benzimidazoles / pharmacokinetics
  • Benzimidazoles / therapeutic use*
  • Helminthiasis / drug therapy*
  • Helminthiasis / epidemiology
  • Humans
  • Infant
  • Soil / parasitology*

Substances

  • Anthelmintics
  • Benzimidazoles
  • Soil